Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 10/20 | 1.00 |
| ▸ | CA2 | P00918 | 10/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 7/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 1.00 |
| ▸ | GAA | P10253 | 5/20 | 1.00 |
| ▸ | MAPT | P10636 | 4/20 | 1.00 |
| ▸ | GLA | P06280 | 4/20 | 1.00 |
| ▸ | HPGD | P15428 | 3/20 | 1.00 |
| ▸ | CFTR | P13569 | 1/20 | 1.00 |
| ▸ | GOPC | Q9HD26 | 1/20 | 1.00 |
| ▸ | ATM | Q13315 | 5/20 | 0.84 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.84 |
| ▸ | CA12 | O43570 | 1/20 | 0.84 |
| ▸ | CA9 | Q16790 | 1/20 | 0.84 |
| ▸ | LMNA | P02545 | 1/20 | 0.84 |
| ▸ | HTT | P42858 | 2/20 | 0.79 |
| ▸ | PDE5A | O76074 | 1/20 | 0.79 |
| ▸ | CDC42 | P60953 | 1/20 | 0.79 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18826388 | 0.92 | CA1 (0.91) | CA1CA2L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL18826375 | 0.92 | CA1 (0.91) | CA1CA2L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL18826376 | 0.92 | CA1 (0.91) | CA1CA2L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL18826389 | 0.89 | L3MBTL1 (1.00) | CA1CA2L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL18826372 | 0.89 | CA2 (0.79) | CA1CA2L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL18826392 | 0.89 | L3MBTL1 (1.00) | CA1CA2L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL15197341 | 0.89 | CA1 (1.00) | CA1CA2L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL12494043 | 0.89 | L3MBTL1 (1.00) | CA1CA2L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL18826377 | 0.89 | L3MBTL1 (1.00) | CA1CA2L3MBTL1KDM4EALDH1A1 | |
| SCHEMBL31429963 | 0.87 | CA1 (0.77) | CA1CA2L3MBTL1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312332-A1 | TREATMENT OF MUSCLE FIBROSIS | FUNDACIÓ INSTITUT DE RECERCA DE L'HOSPITAL DE LA SANTA CREU I SANT PAU (ES) | 2025-10-09 | — | — | US | disclosed |
| WO-2023199010-A1 | TREATMENT OF MUSCLE FIBROSIS | UNIVERSITY OF NEWCASTLE UPON TYNE (GB) | 2023-10-19 | — | — | WO | disclosed |
| US-9642835-B2 | Modulators of GTPase and use in relevant treatment | STC.UNM (US) | 2017-05-09 | — | — | US | disclosed |
| US-9642835-B2 | Modulators of GTPase and use in relevant treatment | STC.UNM (US) | 2017-05-09 | — | — | US | disclosed |
| US-RE39681-E1 | 1-(4-sulfamyaryl)-3-substituted-5-aryl-2-pyrazolines and inhibitors of cyclooxygenase-2 | TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2007-06-05 | — | — | US | disclosed |
| US-20070066651-A1 | Pyrazoline derivatives useful for the treatment of cancer | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312332-A1 | TREATMENT OF MUSCLE FIBROSIS | RHOA, MYLK2, MYLK | CA1 4865/4885CA2 1902/4885L3MBTL1 1969/4885 |
| US-20070066651-A1 | Pyrazoline derivatives useful for the treatment of cancer | PTGIS, PTGS1, PTGIR | CA1 1633/4885CA2 301/4885L3MBTL1 1621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.